157 related articles for article (PubMed ID: 2467347)
21. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
22. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
24. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
26. A comparison between des-gamma-carboxy prothrombin and alpha-fetoprotein as markers of hepatocellular carcinoma in southern African blacks.
King MA; Kew MC; Kuyl JM; Atkinson PM
J Gastroenterol Hepatol; 1989; 4(1):17-24. PubMed ID: 2485005
[TBL] [Abstract][Full Text] [Related]
27. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
28. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kanai T; Umeshita K; Nakano Y; Mori T; Sakurai M; Wakasa K
Am J Surg; 1992 Feb; 163(2):251-6. PubMed ID: 1371207
[TBL] [Abstract][Full Text] [Related]
29. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.
Fujiyama S; Izuno K; Yamasaki K; Sato T; Taketa K
Tumour Biol; 1992; 13(5-6):316-23. PubMed ID: 1283927
[TBL] [Abstract][Full Text] [Related]
30. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
31. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
[TBL] [Abstract][Full Text] [Related]
32. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
[TBL] [Abstract][Full Text] [Related]
33. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma.
Ohhira M; Ohtake T; Saito H; Ikuta K; Tanaka K; Tanabe H; Kawashima T; Fujimoto Y; Naraki T; Ono M; Kohgo Y
Alcohol Clin Exp Res; 1999 Apr; 23(4 Suppl):67S-70S. PubMed ID: 10235282
[TBL] [Abstract][Full Text] [Related]
34. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
35. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
[TBL] [Abstract][Full Text] [Related]
36. [A new method of functional assay of des-gamma-carboxyprothrombin using staphylocoagulase. Application to the diagnosis of hepatocellular carcinoma].
Soulier JP; Gozin D; Lefrère JJ
Presse Med; 1985 Nov; 14(40):2049-52. PubMed ID: 3001686
[TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
38. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
39. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.
Kaibori M; Matsui Y; Yanagida H; Yokoigawa N; Kwon AH; Kamiyama Y
World J Surg; 2004 Jul; 28(7):702-7. PubMed ID: 15185000
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
